Press Detail

PRESS RELEASE

Biotest AG: Annual general meeting approves again increase of dividend

- Distribution of EUR 0.57 per ordinary share and EUR 0.63 per preference share

Dreieich/ Frankfurt a. M., 7 May 2014. At the annual general meeting (AGM) held on 7 May 2014 in Frankfurt am Main shareholders of Biotest AG approved a payment of an increased dividend. With 78.0 percent of the ordinary share capital represented at the meeting, a payment of EUR 0.57 per ordinary share and EUR 0.63 per preference share was resolved with a high degree of approval. The amount of dividends paid increased by 28.2% taking the newly issued preference shares into consideration. The overall distribution will amount to EUR 7.9 million.

The annual general meeting attended by around 180 shareholders and guests also formally discharged the members of the Management Board and Supervisory Board for financial year 2013 and endorsed all of the other agenda items by a large majority.

The full text of the address given by Professor Gregor Schulz at the AGM is available at: http://www.biotest.de/ww/de/pub/investor_relations/ hauptversammlung.cfm.

Disclaimer

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

About Biotest

Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of rheumatoid arthritis and cancer of plasma cells, which are produced by recombinant technologies. Biotest has more than 2.000 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
e-mail: investor_relations@biotest.de
fax: +49 (0) 6103 801-347

Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover, München, Stuttgart